Cellectar Biosciences has announced a decade-long supply agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225 (Ac-225), a key radioisotope in cancer treatment. This agreement is set to provide Cellectar with a stable Ac-225 supply, enabling
NorthStar Medical Radioisotopes, a radiopharmaceutical Contract Development and Manufacturing Organization, officially opened its new Dose Manufacturing Center in Beloit, Wisconsin. The state-of-the-art facility will increase NorthStar’s capacity to support biopharmaceutical companies in the development and production of critical radioisotopes used
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
